A novel missense mutation in the CLCN7 gene linked to benign autosomal dominant osteopetrosis: a case series

Journal of Medical Case Reports

Beston Faiek Nore³  Georgia Lahr²  Ansgar Schulz²  Nawshirwan Gafoor Rashid¹  Ban Mousa Rashid⁴ 

[1] Department of Hematology, Hiwa Hematology-Oncology Center, Kurdistan Regional Government, Sulaimaniyah, Iraq;Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Eythstr. 24, Ulm D-89075, Germany;Department of Biochemistry, School of Medicine, Faculty of Medical Sciences, University of Sulaimani, Kurdistan Regional Government, Sulaimaniyah, Iraq;Department of Biochemistry, School of Pharmacy, Faculty of Medical Sciences, University of Sulaimani, Kurdistan Regional Government, Sulaimaniyah, Iraq

关键词: Osteopetrosis;    Dominant allele;    Consanguineous marriage;    CLCN7 gene;    Autosomal dominant osteopetrosis;   

Others  :  1195151
DOI  :  10.1186/1752-1947-7-7

 received in 2012-04-21, accepted in 2012-11-13,  发布年份 2013

【 摘 要 】

Introduction

Osteopetrosis is a rare inherited genetic disease characterized by sclerosis of the skeleton. The absence or malfunction of osteoclasts is found to be strongly associated with the disease evolution. Currently, four clinically distinct forms of the disease have been recognized: the infantile autosomal recessive osteopetrosis, the malignant and the intermediate forms, and autosomal dominant osteopetrosis, type I and type II forms. The autosomal recessive types are the most severe forms with symptoms in very early childhood, whereas the autosomal dominant classes exhibit a heterogeneous trait with milder symptoms, often at later childhood or adulthood.

Case presentation

Case 1 is the 12-year-old daughter (index patient) of an Iraqi-Kurdish family who, at the age of eight years, was diagnosed clinically to have mild autosomal dominant osteopetrosis. Presently, at 12-years old, she has severe complications due to the disease progression. In addition, the same family previously experienced the death of a female child in her late childhood. The deceased child had been misdiagnosed, at that time, with thalassemia major. In this report, we extended our investigation to identify the type of the inheritance patterns of osteopetrosis using molecular techniques, because consanguineous marriages exist within the family history. We have detected one heterozygous mutation in exon 15 of the Chloride Channel 7 gene in the index patient (Case 1), whereas other mutations were not detected in the associated genes TCIRG1, OSTM1, RANK, and RANKL. The missense mutation (

C

GG>

T

GG) located in exon 15 (c.1225C>T) of the Chloride Channel 7 gene changed the amino acid position 409 from arginine to tryptophan (p.R409W, c.1225C>T).

Case 2 is the 16-year-old son (brother of the index patient) of the same family who was diagnosed clinically with mild autosomal dominant osteopetrosis. We have identified the same heterozygous mutation in exon 15 of the Chloride channel 7 gene in this patient (Case 2). The missense mutation (

C

GG>

T

GG) located in exon 15 (c.1225C>T) of the Chloride channel 7 gene changed the amino acid position 409 from arginine to tryptophan (p.R409W, c.1225C>T).

In addition to the clinical diagnosis of both cases, the missense mutation we identified in one allele of the Chloride channel 7 gene could be linked to autosomal dominant osteopetrosis-II because the symptoms appear in late childhood or adolescence.

Conclusion

In this family, the molecular diagnosis was confirmed after identification of the same mutation in the older son (sibling). Furthermore, we detected that the father and his brother (the uncle) are carriers of the same mutation, whereas the mother and her sister (the aunt) do not carry any mutation of the Chloride channel 7 gene. Thus, the disease penetrance is at least 60% in the family. The mother and father are cousins and a further consanguineous marriage between the aunt and the uncle is not recommended because the dominant allele of the Chloride channel 7 gene will be transferred to the progeny. However, a similar risk is also expected following a marriage between the uncle and an unrelated woman. The p.R409W mutation in the Chloride channel 7 gene has not yet been described in the literature and it possibly has a dominant-negative impact on the protein.

【 授权许可】

   
2013 Rashid et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Stoker DJ: Osteopetrosis. Semin Musculoskelet Radiol 2002, 6:299-305.
• [2]Superti-Furga A, Unger S: Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A 2007, 143:1-18.
• [3]Stark Z, Savarirayan R: Osteopetrosis. Orphanet J Rare Dis 2009, 4:5. BioMed Central Full Text
• [4]Khan MN, Datta PK, Hasan MI, Hossain MA, Patwary KH, Ferdous J: Osteopetrosis. Mymensingh Med J 2011, 20:715-718.
• [5]Balemans W, Van Wesenbeeck L, Van Hul W: A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int 2005, 77:263-274.
• [6]Bollerslev J, Mosekilde L: Autosomal dominant osteopetrosis. Clin Orthop Relat Res 1993, 294:45-51.
• [7]Henriksen K, Gram J, Hoegh-Andersen P, Jemtland R, Ueland T, Dziegiel MH, Schaller S, Bollerslev J, Karsdal MA: Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo. Am J Pathol 2005, 167:1341-1348.
• [8]Van Hul E, Gram J, Bollerslev J, Van Wesenbeeck L, Mathysen D, Andersen PE, Vanhoenacker F, Van Hul W: Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res 2002, 17:1111-1117.
• [9]Bollerslev J, Andersen PE Jr: Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis. Bone 1988, 9:7-13.
• [10]Benichou OD, Laredo JD, de Vernejoul MC: Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients. Bone 2000, 26:87-93.
• [11]Albers-Schönberg HE: Röntgenbilder einer seltenen Knockenerkrankung. Munch Med Wochenschr 1904, 51:365-368.
• [12]Kovacs CS, Lambert RG, Lavoie GJ, Siminoski K: Centrifugal osteopetrosis: appendicular sclerosis with relative sparing of the vertebrae. Skeletal Radiol 1995, 24:27-29.
• [13]Duran C, Thompson CH, Xiao Q, Hartzell HC: Chloride channels: often enigmatic, rarely predictable. Annu Rev Physiol 2010, 72:95-121.
• [14]Jentsch TJ, Stein V, Weinreich F, Zdebik AA: Molecular structure and physiological function of chloride channels. Physiol Rev 2002, 82:503-568.
• [15]Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ: Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001, 104:205-215.
• [16]Letizia C, Taranta A, Migliaccio S, Caliumi C, Diacinti D, Delfini E, D'Erasmo E, Iacobini M, Roggini M, Albagha OM, et al.: Type II benign osteopetrosis (Albers-Schönberg disease) caused by a novel mutation in CLCN7 presenting with unusual clinical manifestations. Calcif Tissue Int 2004, 74:42-46.
• [17]Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, Andolina M, Flanagan A, Horwitz EM, Mihci E, et al.: Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res 2003, 18:1740-1747.
• [18]de Vernejoul MC: Sclerosing bone disorders. Best Pract Res Clin Rheumatol 2008, 22:71-83.
• [19]Zhao Q, Wei Q, He A, Jia R, Xiao Y: CLC-7: a potential therapeutic target for the treatment of osteoporosis and neurodegeneration. Biochem Biophys Res Commun 2009, 384:277-279.
• [20]Pangrazio A, Pusch M, Caldana E, Frattini A, Lanino E, Tamhankar PM, Phadke S, Lopez AG, Orchard P, Mihci E, et al.: Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations. Hum Mutat 2010, 31:E1071-E1080.
• [21]Waguespack SG, Hui SL, Dimeglio LA, Econs MJ: Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J Clin Endocrinol Metab 2007, 92:771-778.
• [22]Zhang ZL, He JW, Zhang H, Hu WW, Fu WZ, Gu JM, Yu JB, Gao G, Hu YQ, Li M, Liu YJ: Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II). J Bone Miner Metab 2009, 27:444-451.
• [23]Ballet JJ, Griscelli C, Coutris C, Milhaud G, Maroteaux P: Bone-marrow transplantation in osteopetrosis. Lancet 1977, 2:1137.
• [24]Nisbet NW, Menage J, Loutit JF: Bone-marrow transplantation in osteopetrosis. Lancet 1977, 2:1236.
• [25]Coccia PF, Krivit W, Cervenka J, Clawson C, Kersey JH, Kim TH, Nesbit ME, Ramsay NK, Warkentin PI, Teitelbaum SL, et al.: Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med 1980, 302:701-708.
• [26]Driessen GJ, Gerritsen EJ, Fischer A, Fasth A, Hop WC, Veys P, Porta F, Cant A, Steward CG, Vossen JM, et al.: Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant 2003, 32:657-663.
• [27]Askmyr MK, Fasth A, Richter J: Towards a better understanding and new therapeutics of osteopetrosis. Br J Haematol 2008, 140:597-609.
• [28]Chen CJ, Lee MY, Hsu ML, Lien SH, Cheng SN: Malignant infantile osteopetrosis initially presenting with neonatal hypocalcemia: case report. Ann Hematol 2003, 82:64-67.
• [29]Waguespack SG, Hui SL, White KE, Buckwalter KA, Econs MJ: Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab 2002, 87:2212-2217.
• [30]Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, Halleen JM: Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schönberg disease (type II autosomal dominant osteopetrosis). Clin Chem 2004, 50:883-890.
• [31]Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, Fortunati D, Ballanti P, Iacobini M, Luciani M, et al.: Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 2006, 43:315-325.
• [32]Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, et al.: Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 2001, 10:2861-2867.
• [33]Weinert S, Jabs S, Supanchart C, Schweizer M, Gimber N, Richter M, Rademann J, Stauber T, Kornak U, Jentsch TJ: Lysosomal pathology and osteopetrosis upon loss of H+−driven lysosomal Cl- accumulation. Science 2010, 328:1401-1403.
• [34]Fotiadou A, Arvaniti M, Kiriakou V, Tsitouridis I: Type II autosomal dominant osteopetrosis: radiological features in two families containing five members with asymptomatic and uncomplicated disease. Skeletal Radiol 2009, 38:1015-1021.